BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00432-010-0922-8.pdf
Reference4 articles.
1. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705–5712
2. Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930
3. Loupakis F, Ruzzo A, Cremolini C et al (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715–721
4. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4:e7287
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment;Exploration;2022-05-09
2. Cetuximab and epirubicin HCl-combined application as a possibility to treat both parental and epirubicin HCl-resistant liver cancer cells;Biologia Futura;2019-09-01
3. Enhanced anticancer effect of cetuximab combined with stabilized silver ion solution in EGFR-positive lung cancer cells;Turkish Journal of Biochemistry;2019-08-17
4. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-TypeBRAF-Expressing Cancer Independent of the Microsatellite Instability Status;Journal of Korean Medical Science;2017
5. Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients;Molecular Biology;2015-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3